Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sprifermin - Merck

Drug Profile

Sprifermin - Merck

Alternative Names: AS-902330; FGF-18; rhFGF-18; Zfgf5

Latest Information Update: 14 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ZymoGenetics
  • Developer Merck Serono; Molecular Therapeutics; Nordic Bioscience; Pfizer
  • Class Fibroblast growth factors; Neuroprotectants
  • Mechanism of Action Fibroblast growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Osteoarthritis
  • Discontinued Cartilage disorders; Stroke

Most Recent Events

  • 08 Oct 2019 Updated efficacy and adverse event data from the FORWARD phase II trial in Osteoarthritis presented in the Journal of the American Medical Association (JAMA)
  • 12 Jun 2019 Updated efficacy data from the FORWARD phase II trial in Osteoarthritis presented at the 20th Annual Congress of the European League Against Rheumatism (EULAR-2019)
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top